RALGAPA1: A Drug Target and Potential Biomarker (G253959)

Target Name: RALGAPA1

NCBI ID: G253959

RALGAPA1: A Drug Target and Potential Biomarker

RalGAPA1, or Ral GTPase activating protein alpha subunit 1, is a protein that plays a crucial role in the regulation of cell signaling pathways. It is a member of the GTPase family, which includes proteins that activate the protein GTPase, a key intermediate step in the intracellular signaling cascade. The RalGAPA1 gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The RalGAPA1 protein is composed of 214 amino acid residues and has a calculated molecular mass of 24.3 kDa. It consists of a catalytic alpha subunit and a regulatory beta subunit. The alpha subunit contains the protein's active site, which is responsible for the catalytic activity of the protein. The beta subunit contains a N-terminal region that is involved in the regulation of the alpha subunit's activity and a C-terminal region that contains a conserved Asp-Glu-Pro-Glu loop, which is known to play a role in the regulation of protein stability and can modulate the activity of the alpha subunit.

RalGAPA1 is involved in the regulation of several cellular processes, including cell signaling, cell growth, and cell differentiation. It is a key regulator of the RalA1-GTPase (RalGAPA), which is associated in the regulation of cell signaling pathways, including cell proliferation, migration, and invasion. The RalGAPA1-associated GTPase is a protein that is activated by GTP and then regulates the activity of several downstream effectors, including the protein Pyknot, which is involved in the regulation of microtubule dynamics.

In neurodegenerative diseases, RalGAPA1 has been implicated in the pathogenesis of various disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that RalGAPA1 is expressed abnormally in the brains of individuals with these disorders and that its activity is modulated by factors such as GNPQ, a neurodegenerative protein that is known to interact with RalGAPA1.

In cancer, RalGAPA1 has been identified as a potential drug target and biomarker. Studies have shown that RalGAPA1 is expressed in various types of cancer and that its activity is modulated by factors such as GTP and pH, which are known to play a role in the regulation of cancer cell growth and survival. Additionally, RalGAPA1 has been shown to be involved in the regulation of the G1/S transition, a critical step in the cell cycle that is involved in the development of cancer cells.

As a potential drug target, RalGAPA1 has been the focus of research in the laboratory and in clinical trials. Studies have shown that inhibiting the activity of RalGAPA1 can lead to a variety of cellular and molecular changes, including the inhibition of cell proliferation, apoptosis, and migration. Additionally, RalGAPA1 has been shown to play a role in the regulation of cellular processes that are important in the development of neurodegenerative diseases, including the regulation of microtubule dynamics and the regulation of the G1/S transition.

In addition to its potential as a drug target, RalGAPA1 has also been identified as a potential biomarker for a variety of diseases. Studies have shown that RalGAPA1 is expressed in various types of cancer and that its activity is modulated by factors such as GTP and pH , which are known to play a role in the regulation of cancer cell growth and survival. Additionally, RalGAPA1 has been shown to be involved in the regulation of the G1/S transition, a critical step in the cell cycle that is involved in

Protein Name: Ral GTPase Activating Protein Catalytic Subunit Alpha 1

Functions: Catalytic subunit of the heterodimeric RalGAP1 complex which acts as a GTPase activator for the Ras-like small GTPases RALA and RALB

More Common Targets